Protocol to Obtain Bone Marrow for Research
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Potential donors who are undergoing bone marrow biopsy or bone marrow donation as part of clinical care will be asked by the principal investigator (PI) if they might be interested in donating marrow for this research project. If they are interested, the PI will meet with the prospective donor to review the information contained in the informed consent document and to answer any questions the potential subject may have. Bone marrow aspirates of approximately 5cc will be obtained from the posterior iliac crest of subjects using standard techniques.
| Condition | Intervention |
|---|---|
|
Bone Marrow Biopsy |
Other: Bone Marrow Aspirate Draw |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort |
| Official Title: | Protocol to Obtain Bone Marrow for Research |
5cc of bone marrow aspirate
| Estimated Enrollment: | 100 |
| Study Start Date: | June 2005 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| No Treatment |
Other: Bone Marrow Aspirate Draw
5cc of Bone Marrow Aspirate will be drawn
|
Detailed Description:
The purpose of this study is to determine the mechanisms that regulate human globin gene expression by analyzing the function of cell signaling pathways and the expression of other related genes and their protein products in the bone marrow cells of people without blood diseases. This includes the effects of drugs and other in vitro manipulations of the cells once they are removed from donors. These assays will include, but are not limited to, determinations of DNA methylation status, histone acetylation profiles, DNAse sensitivity, transcription factor binding to DNA, levels of various proteins, messenger RNAs and miRNAs in the cells of the marrow samples. By understanding how this process occurs in people without blood diseases, we hope to to design future treatments for people with diseases such as sickle cell disease and B-thalassemia.
Eligibility| Ages Eligible for Study: | 17 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
- Patients undergoing diagnostic bone marrow biopsies at the Norris Cotton Cancer Center of Dartmouth Hitchcock Medical Center (DHMC).
- Patients undergoing bone marrow harvesting for autologous bone marrow transplantation.
Inclusion Criteria:
- Patients undergoing diagnostic bone marrow biopsies at the Norris Cotton Cancer Center of DHMC.
- Patients undergoing bone marrow harvesting for autologous bone marrow transplantation.
- Normal donors undergoing bone marrow harvesting for autologous bone marrow transplantation.
- Normal persons over the age of 17 who volunteer to undergo bone marrow aspiration.
Exclusion Criteria:
- Normal volunteers with known allergies to lidocaine (or similar analgesics)or betadine.
Contacts and Locations| Contact: Research Nurse | 800-639-6918 | cancer.research.nurse@dartmouth.edu |
| Contact: Nancy Rollings | 603-650-5135 | Nancy.J.Rollings@Hitchcock.org |
| United States, New Hampshire | |
| Dartmouth-Hitchcock Medical Center | Recruiting |
| Lebanon, New Hampshire, United States, 03756 | |
| Principal Investigator: Christopher H Lowrey, MD | |
| Principal Investigator: | Christopher H Lowrey, MD | Dartmouth-Hitchcock Medical Center |
More Information
No publications provided
| Responsible Party: | Dartmouth-Hitchcock Medical Center |
| ClinicalTrials.gov Identifier: | NCT00951925 History of Changes |
| Other Study ID Numbers: | D0529 |
| Study First Received: | August 3, 2009 |
| Last Updated: | February 13, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Dartmouth-Hitchcock Medical Center:
|
Any patient undergoing diagnostic bone marrow biopsies Any patient undergoing bone marrow harvesting for autologous bone marrow transplantation. |
ClinicalTrials.gov processed this record on May 23, 2013